There's a debate about whether there is enough competition to spur innovation. Some economists have done studies showing that the rate of innovation has slowed down, particularly in pharma and tech in the United States. Jim Boulden: I'm just thinking about, you know, the innovation that spurred the mRNA vaccines didn't come from big pharma. That came from smaller players.
Bloomberg Intelligence Senior Litigation Analyst, Jennifer Rie and Bloomberg Antitrust Reporter Leah Nylen discuss the latest with the FTC’s suit to block Amgen’s deal with Horizon Therapeutics. Mary Lou Gardner, Associate Partner for CPG, Retail and Logistics at Infosys Consulting discusses consumer outlook in retail. Bloomberg Businessweek Editor Joel Weber and Bloomberg Editorial Senior Commodities Reporter James Attwood discuss the green energy transition and Chile’s copper problem. And we Drive to the Close with Hank Smith, CIO of Haverford Trust.
Hosts: Carol Massar and Matt Miller. Producer: Sara Livezey
See omnystudio.com/listener for privacy information.